Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study

Abstract

Oxaliplatin/GEM (arm C) had similar activity to carboplatin/GEM (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplatin/GEM in patients not suitable for cisplatin. The sequential regimen gave no additional benefit.

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies

“…Regarding whether Arg399Gln acts as a suitable marker for predicting the (Wang et al, 2004;Kalikaki et al, 2009;Ding et al, 2010;Qian et al, 2010;Zhou et al, 2011;Li et al, 2012) suggested that Arg399Gln is able to predict the ORR, four articles (Gao et al, 2006;Sun et al, 2009;Yao et al, 2009;Joerger et al, 2012) found no relationship between Arg399Gln and ORR, and two papers (Fan et al, 2008;Yao et al, 2010) noted differences that did not reach statistical significance. Five papers (Gurubhagavatula et al, 2004;de las Penas et al, 2006;Liu et al, 2008;Kalikaki et al, 2009;Joerger et al, 2012) concluded that Arg399Gln is a prognostic factor while three (Giachino et al, 2007;Yao et al, 2009;Dong et al, 2012) found no significant correlation between XRCC1 genotype and prognosis. Of the 2 256 cases included in this meta-analysis, 1 520 were Asian and 736 Caucasian.…”

“…Twelve papers were excluded due to insufficient data. Finally, a total of 17 studies (Gurubhagavatula et al, 2004;Wang et al, 2004;de las Penas et al, 2006;Gao et al, 2006;Giachino et al, 2007;Fan et al, 2008;Liu et al, 2008;Kalikaki et al, 2009;Sun et al, 2009;Yao et al, 2009;Ding et al, 2010;Qian et al, 2010;Zhou et al, 2011;Dong et al, 2012;Joerger et al, 2012;Li et al, 2012) were included in the final meta-analysis. Ten of these were written in English (Gurubhagavatula et al, 2004;de las Penas et al, 2006;Giachino et al, 2007;Kalikaki et al, 2009;Sun et al, 2009;Yao et al, 2009;Zhou et al, 2011;Dong et al, 2012;Joerger et al, 2012;Li et al, 2012) and the other seven in Chinese (Wang et al, 2004;Gao et al, 2006;Fan et al, 2008;Liu et al, 2008;Ding et al, 2010;Qian et al, 2010;Yao et al, 2010).…”

“…Eight papers included survival, seven of which directly reported OS and HR (Gurubhagavatula et al, 2004;de las Penas et al, 2006;Giachino et al, 2007;Kalikaki et al, 2009;Yao et al, 2009;Dong et al, 2012;Joerger et al, 2012), while the remaining article (Liu et al, 2008) calculated HR and 95% CI according to the statistical method mentioned above. We divided all studies into two groups based on the reported data; investigations reporting the ORR usually originated from Asian populations (10/12), whereas studies conducted in regions with Caucasian majorities selected survival time as the main outcome indicator.…”

“…Eight papers reported OS, three of which (Gurubhagavatula et al, 2004;Giachino et al, 2007;Joerger et al, 2012) reported HR using AA as the reference value, three (Liu et al, 2008;Kalikaki et al, 2009;Dong et al, 2012) reported HR using GG as the reference value, and the other two papers (de las Penas et al, 2006;Yao et al, 2009) yielded limited data. The median OS for AA, AG, and GG was 14.2, 15.4, and 16.1 months, respectively.…”

“…Tyrosine kinase inhibitors (TKIs) are also frequently used, but platinum-based therapy remains the best option for the treatment of advanced NSCLC when the mutation status of the epidermal growth factor receptor (EGFR) is unknown (Bidoli et al, 2007;Jemal et al, 2009;Vilmar and Sørensen, 2009;National Comprehensive Cancer Network, 2011). However, the development of platinum-based therapies has slowed and many NSCLC patients derived little therapeutic benefit from any of those currently available (Shellard et al, 1993;Pfister et al, 2004;Wang et al, 2011).…”